O ne emerging and important class of nanomaterials, polyvalent DNAfunctionalized gold nanoparticles (DNAÀAuNPs), has been studied and utilized extensively in the fields of biodiagnostics, gene regulation, and nanomedicine.
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The fundamental properties of these particles, including sharp melting transitions when bound to complementary nucleic acid sequences, catalytic activity, and enhanced target binding, have made them extremely useful in the context of biological detection schemes. 5 These materials also have attractive characteristics and properties that make them excellent candidates for drug delivery applications. 4 The dense shell of synthetic oligonucleotides allows DNAÀ AuNPs to be easily dispersed without solvent-induced aggregation in aqueous systems, including buffers with high concentrations of salts and serum-containing cell culture media. In addition, the high surface density of oligonucleotides creates a high local ion concentration, which results in resistance to enzymatic nucleic acid degradation. 7 DNAÀAuNPs are efficiently taken up in high numbers by over 50 different cell lines (including neurons) and primary cells. 4 This almost universal cell-uptake property has been attributed to the dense loading of the oligonucleotides on the AuNPs and their ability to bind scavenger proteins and facilitate endocytosis. 5, 8 DNAÀAuNPs can be readily modified with a wide variety of compounds using straightforward alkylthiol adsorption on gold chemistry. 1,4,5,9À16 In particular, recent reports show that the polyvalent attachment of platinum drugs and magnetic resonance imaging (MRI) contrast agents onto DNAÀAuNPs results in enhanced cellular uptake and activity. 10 Although
DNAÀAuNPs have been extensively studied, they exhibit no apparent cytotoxicity and elicit little innate immune response, 6, 17 alluding to their potential as nontoxic and biocompatible nanomaterials, which may be suitable for clinical use. This property alone potentially overcomes one of the greatest concerns regarding nanomaterials in drug delivery, which to date has limited their widespread use in biomedical applications.
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Attractive due to their enhanced cellular uptake, stability, biocompatibility, and versatile surface functionalization, DNAÀ AuNPs are also a potentially useful system for the delivery of hydrophobic chemotherapeutic agents. 4 Here we describe the synthesis and characterization of novel PaclitaxelÀDNA@AuNP conjugates within the context of in vitro drug delivery. Paclitaxel, derived from the bark of the pacific yew tree, is one of the most active chemotherapeutic agents used for the treatment of various cancers, especially ovarian, breast, and nonsmall cell lung cancers for the past decade. 21, 22 As a mitotic inhibitor, Paclitaxel exerts its cytotoxic effect by arresting mitosis through microtubule stabilization and subsequently interfering with the normal breakdown of microtubules during cell division, resulting in cellular apoptosis. 22, 23 Although Paclitaxel has had a significant impact in cancer treatment, the effectiveness of traditional Paclitaxel-based treatment regimens has been limited due to the drug's low aqueous solubility, eventual acquired chemoresistance of cells, and certain side effects. 24 Its commercial formulation, Taxol (Bristol-Myers Squibb), is formulated in a high concentration in Cremophor EL, a solvent and excipient material that is necessary to solubilize Paclitaxel but can cause severe side effects, including hypersensitivity reactions, nephrotoxicity, myelosuppression, and peripheral neuropathy. 25, 26 The emerging macroparticle or nanoparticle-based delivery approaches have provided interesting avenues for improving cancer treatments by the controlled delivery and release of chemotherapeutic agents. 27À37 Among them, several strategies for increasing Paclitaxel solubility and efficacy have been studied, such as the use of emulsification, micellization, liposomes, nonliposomal carriers (microspheres, nanoparticles), cyclodextrins, and local drug delivery devices. 25 Most of these delivery strategies are focused upon encapsulation methods, 31, 38 which have been shown to yield particles with high loading and relatively large size (100 nm to micrometer size). 39À41 Interestingly, drugÀnanoparticle hybrid conjugates have recently garnered significant attention. 27, 42 The smaller structures (<100 nm) made via this method are more stable, can evade reticuloendothelial system (RES) capture, and exhibit the ability to accumulate in a broader range of tumors creating a necessity for In the study reported herein, Paclitaxel molecules are covalently attached to gold nanoparticles via fluorescent oligonucleotide linkers, resulting in a multimodal drug delivery system with simultaneous capabilities in imaging and enhanced therapy. The potency of the resulting conjugates was also tested within a chemoresistant cell line. The data suggest that these conjugates may solve three common problems associated with Paclitaxel as an effective chemotherapeutic agent. First, they enhance the solubility of the drug in aqueous systems such as buffers containing high concentrations of salts and serum-containing cell culture media. Second, they increase drug efficacy in Paclitaxel-resistant cell lines. Third, they provide a useful way of tracking the movement of the conjugates and delivery of the drug. Indeed, these nanoparticle conjugates form the basis for a new strategy for generally increasing drug solubility and efficacy while simultaneously tracking intracellular uptake.
RESULTS AND DISCUSSION
Nanoparticle conjugates were prepared by reacting citrate-stabilized gold nanoparticles with thiolated 20-mer poly-dT oligonucleotides containing a terminal Paclitaxel group (Scheme 1). First, DNA oligomers were synthesized with a terminal amine group for covalent ARTICLE attachment to Paclitaxel. Paclitaxel was modified by reaction with succinic anhydride to create a Paclitaxel carboxylic acid derivative, compound 1. The amineterminated DNA and the Paclitaxel carboxylic acid derivative 1 were covalently attached to each other via EDC/sulfo-NHS coupling chemistry to yield compound 2 (Scheme 1). After purification by RP-HPLC, the PaclitaxelÀDNA (PTXÀDNA) compound 2 was characterized by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), which confirmed its formation ( Figure 1) . Compound 2 was then immobilized on citrate-stabilized AuNPs using literature procedures for making analogous DNAÀAuNPs, 46 ultimately yielding the PaclitaxelÀDNA gold nanoparticle conjugates (PTXÀDNA@AuNPs) 3. Excess PTXÀ DNA was removed through repeated centrifugation and resuspension of PTXÀDNA@AuNPs until no PTXÀ DNA was detected by MALDI-MS in the supernatant. Fluorescein-labeled PTXÀDNA conjugates were synthesized as described in Scheme 1 in order to produce fluoresceinÀPTXÀDNA@AuNPs. These fluorophore-labeled structures were used for confocal microscopy imaging experiments and to determine subsequent loading of Paclitaxel onto the nanoparticle conjugates. In order to determine the number of Paclitaxel molecules loaded on each particle, the fluorescent PTXÀDNA immobilized on the gold nanoparticle surface was chemically released from the particle by an exchange reaction with dithiothreitol (DTT), and the concentrations of fluorescent PTXÀDNA and nanoparticles were measured as described previously for DNAÀAuNPs. 46 The average number of Paclitaxel molecules per nanoparticle was determined to be 59 ( 8 by dividing the concentration of fluorescent oligonucleotides by the concentration of nanoparticles.
The aqueous suspension of the PTXÀDNA@AuNP conjugates is deep red in color due to the plasmon resonance of the Au nanoparticles at 520 nm ( Figure 2A ). The conjugates show no evidence of degradation after 2 months when stored at 4°C as an aqueous solution, in contrast with unconjugated Paclitaxel (at a comparable concentration) in PBS, which forms a cloudy suspension consisting of precipitated Paclitaxel ( Figure 2A ). UVÀvis spectroscopy of the PTXÀDNA@ AuNPs confirms that the particles remain dispersed in solution after drug conjugation ( Figure 2B ); aggregation would result in a highly diagnostic red shift in the surface plasmon resonance for the colloid. 3 Furthermore, it is interesting to note that the drugÀnanoparti-cle conjugates 3 exhibit significantly enhanced solubility in salt-containing buffer. Dynamic light scattering (DLS) analysis and TEM images ( Figure 3 ) indicate that the PTXÀDNA@AuNPs are well-dispersed in PBS with a narrow size distribution, whereas severe aggregation ARTICLE occurs when the same amount of hydrophobic Paclitaxel (25 μM Paclitaxel) is suspended by sonication for several seconds in PBS. When compared with unmodified DNAÀAuNPs (29.2 ( 0.6 nm), PTXÀDNA@AuNPs exhibit a slightly larger average size (34.7 ( 1.7 nm) with a polydispersity index (PDI) of 0.2. As previously reported, free Paclitaxel has a maximum solubility of 0.4 μg/mL in aqueous solution. 47 In contrast, the conjugated PTXÀDNA@AuNPs were stable in PBS buffer solution at the equivalent Paclitaxel concentration of 21.35 μg/mL (25 μM). This represents a greater than 50-fold enhancement in drug solubility when they were bound to the AuNPs compared to free drug. As summarized in Table S1 (Supporting Information), the PTXÀDNA@AuNPs are still stable when exposed to Eagle's minimum essential medium (EMEM) at 25 and 37°C. Previous reports have shown that the therapeutic effects of drug-loaded nanoparticles often depend on successful internalization and sustained retention by diseased cells. 31, 48 In this work, we selected DNAÀ AuNPs as a delivery vehicle for Paclitaxel specifically due to the ability of DNAÀAuNPs to enter cells effectively, without the use of transfection reagents. 4 Indeed, DNAÀAuNPs show superior cellular uptake when compared to other types of AuNPs. For example, HeLa cells internalize only a few thousand citrate-coated gold nanoparticles, 49 compared to over one million DNAÀ AuNPs under nearly identical conditions. 8 The cellular uptake of fully oligoethylene glycol-functionalized particles were 3 orders of magnitude lower than DNAÀAuNPs. 8 The ability of fluoresceinÀPTXÀDNA@AuNPs to enter cells was investigated by confocal microscopy using gold nanoparticles functionalized with a monolayer of fluorescein-labeled PTXÀDNA molecules (Figure 4 ). Confocal fluorescence images show the successful internalization of the fluorophore-labeled conjugates in MCF7 human breast adenocarcinoma cells and MES-SA/Dx5 human uterine sarcoma cells after 6 h of incubation. Within both cell lines, the fluoresceinÀPTXÀDNA@ AuNPs are observed in the cytoplasm, indicating the efficient translocation of the PaclitaxelÀgold nanoparticle conjugates.
In order to test the activity of the nanoparticle conjugate, a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 50 was performed to measure DNA fragmentation and apoptosis induced by Paclitaxel. MCF7 or MES-SA/Dx5 cells were incubated with drug-free DNAÀAuNPs, free Paclitaxel, compound ARTICLE enhanced cellular uptake of the conjugates in comparison with free drug. In addition, the results suggest that nanoparticle-mediated drug delivery can potentially overcome the cellular cross resistance of a number of chemotherapeutic agents in vitro. Multiple drug resistance (MDR) often occurs when transporter proteins that expel drugs from cells are overexpressed on the surface of cancer cells. 51 ,54À56 Nanoparticles can reduce the chemoresistance that characterizes many anticancer drugs, including Paclitaxel, by facilitating the internalization of the drug 31, 57 and reducing its efflux from cells mediated by P-glycoprotein (P-gp).
58À63
The effect in MCF7, SKOV-3, and MES-SA/Dx5 cells after incubation at various drug concentrations can be determined by comparing IC 50 
CONCLUSION
In conclusion, we have developed an effective chemical strategy for delivering hydrophobic Paclitaxel while simultaneously overcoming drug efflux in human cancer cells. Covalently attaching hydrophobic Paclitaxel onto gold nanoparticles via a DNA spacer resulted in significantly enhanced hydrophilicity and stability as compared to free Paclitaxel alone. The visualization of fluorescein-labeled PTXÀDNA@AuNPs within human breast adenocarcinoma cells and uterine sarcoma cells by confocal fluorescence microscopy demonstrates the cellular internalization, delivery, and distribution of Paclitaxel. Furthermore, the cell-killing activity of Paclitaxel was enhanced in vitro against several cancer cell lines when attached onto DNAÀAuNPs. In TUNEL and MTT assays across several concentrations and cell lines, PTXÀDNA@AuNPs 3 were more effective than free drug in inducing apoptosis, most notably within Paclitaxel-resistant MES-SA/ Dx5 cells. While continued work investigating the mechanism of enhanced efficacy, biodistribution, pharmacokinetic, and pharmacodynamic of PTXÀDNA@ AuNPs in vivo are being explored, the approach presented here could be easily extended to include other biologically relevant components, such as peptides, 9 small interfering RNA (siRNA), 11 gadolinium complexes, 10 antibodies, 64 and aptamers, 65 allowing for additional modalities to be introduced by utilizing functional groups presented on a DNA linker. Indeed, DNAÀAuNPs are becoming a powerful new platform for combinational therapy, bioimaging, and biodiagnostics.
MATERIALS AND METHODS
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide (sulfo-NHS) were purchased from Thermo Fisher Scientific (Rockford, IL, USA). All other materials and solvents were purchased from SigmaAldrich Chemical Co. (St. Louis, MO, USA) and used without further purification unless noted. Citrate-stabilized AuNPs (13 ( 1.0 nm diameter) were prepared by the Frens method, 66 resulting in ∼10 nM solutions. Compound 1 was synthesized by succinic anhydride according to the literature, 67 adding a carboxyl acid group on the molecule at the C- Synthesis of PaclitaxelÀOligonucleotide Conjugate 2. Oligonucleotides were synthesized on an Expedite 8909 nucleotide synthesis system (ABI) using standard solid-phase phosphoramidite methodology. Bases and reagents were purchased from Glen Research (Sterling, VA, USA). The oligonucleotide used to functionalize the AuNPs was amine-functionalized strand 5 0 -NH 2 -T20-hexyldisulfide-3 0 . The oligonucleotide was purified by reverse-phase high-performance liquid chromatography (RP-HPLC) and characterized by MALDI-MS (Bruker Apex III, Integrated Molecular Structure Education and Research Center, Northwestern University). The concentration of oligonucleotide was determined by monitoring the absorbance at 260 nm with a UVÀvis spectrophotometer. The strand was then reacted with 1 via EDC/sulfo-NHS chemistry to prepare the PTXÀDNA conjugate. In a typical reaction, 0.5 mL of compound 1 in acetonitrile solution was added to 1 mL of 10 times molar excess of sulfo-NHS and EDC solution in HEPES buffer (0.1 M, pH = 7). The resultant mixture was allowed to react at room temperature for 15 min. Then, 0.5 molar equiv (relative to 1) of oligonucleotide strand 5 0 -NH 2 -T20-hexyldisulfide-3 0 was added to the solution. The reaction mixture was shaken gently for 3 days at room temperature. The PTXÀDNA conjugate was purified by RP-HPLC and characterized by MALDI-MS ( Figure S1 ). For quantification ARTICLE of Paclitaxel loaded on the nanoparticle and cellular imaging, an additional fluorescein/amine-modified strand (5 0 -NH 2 -T9-(fluorescein-dT-phosphoramidite)-T10-hexyldisulfide-3 0 ) was synthesized and reacted in a similar fashion to obtain a fluorescein-labeled PTXÀDNA conjugate 2.
Preparation of PTXÀDNA@AuNPs and FluoresceinÀPTXÀDNA@AuNPs 3. The oligonucleotide AuNP conjugates were synthesized as described previously. 46 Briefly, disulfide-functionalized oligonucleotides were freshly cleaved by dithiothreitol (DTT) for 1 h at room temperature prior to use. The cleaved oligonucleotides were purified using NAP-10 columns (GE Healthcare). Freshly cleaved oligonucleotides were then added to gold nanoparticles (1OD/1 mL). After a 16 h incubation, the concentrations of PBS and sodium dodecyl sulfate (SDS) were brought to 0.01 M and 0.01%, respectively. The oligonucleotide/gold nanoparticle solution was allowed to incubate at room temperature for 20 min. NaCl was added using 2 M NaCl with repeated salting increments of 0.02 M NaCl every 5 h until a concentration of 0.1 M NaCl was reached while maintaining an SDS concentration of 0.01%. The salting process was followed by an overnight incubation at room temperature. The final conjugates were stored in buffer with excess oligonucleotides at 4°C. Before use, the PTXÀDNA@AuNP or fluoresceinÀPTXÀDNA@AuNP 3 were spun down and washed until there were no strands detected by MALDI-MS in the supernatant.
Quantification of Alkanethiol Oligonucleotides Loaded on Gold Nanoparticles. The number of oligonucleotides loaded on each particle was determined by measuring the concentration of nanoparticles and the concentration of fluorescent DNA in each sample as previously reported. 46 The concentration of gold nanoparticles in each aliquot was determined by performing UVÀvis spectroscopy measurements. These absorbance values were then related to the nanoparticle concentration via Beer's law (A = εbc). The wavelength of the absorbance maxima (λ) and extinction coefficients (ε) used for 13 nm gold nanoparticles are as follows: λ = 520 nm, ε = 2.7 Â 10 8 M À1 cm
À1
. In order to determine the concentration of fluorescent oligonucleotides in each aliquot, DNA was chemically displaced from the nanoparticle surface using 1.0 M DTT in 0.18 M PBS, pH 8.0. The oligonucleotides were cleaved from the nanoparticle surface into solution during an overnight incubation, and the gold precipitate was subsequently removed by centrifugation. To determine oligonucleotide concentration, 100 μL of supernatant was placed in a 96-well plate and the fluorescence was compared to a standard curve prepared with the same 1.0 M DTT buffer solution. During fluorescence measurements, the fluorophore was excited at 490 nm and the emission was collected at 520 nm.
The number of oligonucleotides per particle for each aliquot was calculated by dividing the concentration of fluorescent oligonucleotides by the concentration of nanoparticles. The experiment was repeated three times using fresh samples to obtain reliable error bars.
Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). PTXÀDNA@AuNPs or DNAÀAuNPs were resuspended in 200 μL PBS buffer with oligonucleotide strands of an equivalent concentration of 25 μM. Hydrodynamic size measurements were conducted using the Zetasizer Nano ZS (Malvern, Worcestershire, U.K.). The size measurements were performed at 25°C at a 173°scattering angle in disposable microcuvettes (minimum volume 40 μL, Malvern, Worcestershire, U.K.). The mean hydrodynamic diameter was determined by cumulative analysis.
TEM was performed using a 200 kV Hitachi H-8100 TEM (EPIC, Northwestern University). Diluted PTXÀDNA@AuNPs in deionized water were pipetted onto a commercial carbon TEM grid (Ted Pella Inc., Redding, CA). Upon air drying for 2 h, samples were then observed within a Hitachi H-8100 TEM.
General Cell Culture. MCF7, SKOV-3, and MES-SA/Dx5 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Media, Dulbecco's phosphate buffered saline (DPBS), and 0.25% trypsin/EDTA were purchased from Invitrogen (Carlsbad, CA, USA). MCF7 cells were cultured in Eagle's minimum essential medium (EMEM) supplemented with 10% fetal bovine serum (FBS) and 0.01 mg/mL bovine insulin. SKOV-3 and MES-SA/Dx5 cells were cultured using McCoy's 5A modified media supplemented with 10% FBS. All experiments were performed in the aforementioned cell-specific media in a 5% CO 2 incubator at 37°C.
Fluorescence Imaging. MCF7 and MES-SA/Dx5 cells were grown on Lab-Tek II Chamber #1.5 German coverglass system (Thermo Scientific-Nunc International, Naperville, IL, USA) for 24 h prior to imaging. Then, 0.42 nM fluoresceinÀPTXÀDNA@ AuNPs 3 (corresponding to fluorescein-labeled strands with a concentration of 25 nM) were then added directly to the cell culture media. After 6 h treatment, cells were rinsed with PBS and fresh media added. Live cells were stained with Cellular Lights Actin-RFP (Invitrogen) and DRAQ5 (Biostatus Ltd.) for cytoplasmic actin staining and nuclear staining, respectively, according to manufacturer's instructions. Images were acquired on a Zeiss LSM 510 inverted microscope (computer controlled using Zeiss Zen software). An Appochromat water immersion objective (40Â, NA 1.2) was used for all measurements.
TUNEL Assay. MCF7 and MES-SA/Dx5 cells were seeded on 0.17 mm thick coverslips in 12-well plates at a density of 2 Â 10 5 cells/well for 24 h prior to fluorescent TUNEL assay. Cells were treated with nothing, DNAÀAuNPs at a DNA strand concentration of 100 nM (negative controls), 100 nM of free Paclitaxel and compound 1 (positive controls), and PTXÀDNA@AuNPs at the equivalent Paclitaxel concentrations of 50 and 100 nM (samples), respectively, for 48 h. Live cells were rinsed and stained in accordance with instructions and materials for adherent cultured cells provided by Chemicon International ApopTag Plus fluorescein in situ apoptosis detection kit S7111 (Temecula, CA). ApopTag utilizes the terminal deoxynucleotidyl transferase (TdT) enzyme to amplify the fluorescein-conjugated antidigoxigenin antibody, a secondary antibody toward digoxigeninlabeled nucleotide-labeled 30-OH termini on DNA fragments. Images were acquired on a Zeiss LSM 510 inverted microscope (computer controlled using Zeiss Zen software).
MTT Assay. The cytotoxicity profiles of PTXÀDNA@AuNP conjugates, Paclitaxel and compound 1 in MCF7, MES-SA/Dx5, and SKOV-3 cells were investigated using a 3-(4,5-dimethylthiazol-2-yl-)-2,5-diphenyltetrazolium bromide (MTT) assay following the manufacturer's protocol. Briefly, cells were seeded on 96-well plates for 24 h before the assay at a density of 1.5 Â 10 4 cells/well. Following 24 h growth, medium was replaced with 200 μL of corresponding sample solutions, which were freshly prepared at varying concentrations in complete cell culture media. Cells in media containing 10% FBS with nothing added were used as controls. After 12 or 48 h treatment, cells were rinsed and cultured with fresh medium containing 0.5 mg/mL of MTT for an additional 3 h. Following careful aspiration of MTT solution and media after MTT incubation, 200 μL of MTT solubilization solution was added to each well and thoroughly mixed. The optical density at 570 nm was measured using a Safire microplate reader (Tecan Systems, Inc., San Jose, CA). Background absorbance at 690 nm was subtracted. Values were expressed as a percentage of the control (incubated with media alone). All conditions were done in sextuplicate in two independent experiments for each cell line. 
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Supporting Information Available: Supporting material includes the MTT assay of DNAÀAuNPs containing equivalent DNA strand concentrations in MCF7 and MES-SA/Dx5 cells, and the DLS measurements of PTXÀDNA@AuNPs exposed to PBS and EMEM at various temperatures. This material is available free of charge via the Internet at http://pubs.acs.org.
